Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Onradivir and Oseltamivir in Healthy Subjects
NCT05108051Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Nov 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anlatrelvir in Influenza A (IAV) (3 arms), sponsored by Raynovent Biotech. Primary endpoints: Plasma pharmacokinetics and Treatment-Emergent Adverse Events up to 37 days. Started Nov 2020; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT05108051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108051.